<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0"/>
  <link rel="stylesheet" href="style.css"/>
  <title>MKC Biotherapeutics</title>
</head>
<body>

  <!-- Header -->
  <header>
    <img src="logo.svg" alt="MKC Biotherapeutics Logo" class="logo" />
    
    <!-- Desktop Navigation -->
    <nav class="main-nav">
      <a href="#">About Us</a>
      <a href="#">Our Science</a>
      <a href="#">Clinicians & Patients</a>
      <a href="#">Partners & Investors</a>
      <a href="#">News & Events</a>
      <a href="#">Contact Us</a>
    </nav>

    <!-- Hamburger Icon -->
    <button class="hamburger" aria-label="Toggle menu" onclick="toggleMenu()">â˜°</button>
  </header>

  <!-- Fullscreen Mobile Menu -->
  <div id="mobile-menu" class="mobile-menu" aria-hidden="true">
    <button class="close-btn" aria-label="Close menu" onclick="toggleMenu()">âœ•</button>
    <a href="#">About Us</a>
    <a href="#">Our Science</a>
    <a href="#">Clinicians & Patients</a>
    <a href="#">Partners & Investors</a>
    <a href="#">News & Events</a>
    <a href="#">Contact Us</a>
  </div>

  <!-- Main Content -->
  <main>
    <!-- Introduction Section -->
    <section class="intro">
      <h1>Osteoarthritis of the Knee</h1>
      <div class="content">
        <!-- Left: Text -->
        <div class="text">
          <p>
            Osteoarthritis (OA) is one of the most common debilitating diseases experienced within an ageing population and constitutes an urgent medical need. Obesity, a major risk factor, is further increasing prevalence and occurrence of OA. Approximately 30% of the global population over 60 years of age, suffers from OA and have no disease modifying treatment options. OA largely affects weight bearing joints such as the knee joint & hip joint amongst others. Existing treatment options available include NSAIDs, glucosamine & chondroitin sulphate, Hyaluronic Acid injections (HA), Diacerin (IL-1 inhibitor), or steroid injections. All of these treatments focus on providing temporary pain relief and reducing inflammation during early stages of disease without affecting the course of the disease. All patients ultimately, if able to undergo surgery, will require total knee replacement.
          </p>
          <p>
            Our in-licensing partner has developed and obtained marketing authorization Stem-One Cell Drug Product for treatment of Grade 2&3 Knee OA patients in India. Results from randomized, blinded, placebo-controlled trials with single injection of Stempeucel-OA [CTRI/2018/09/015785 (National Institutes of Health and Clinical Trials Registry-India)] demonstrated statistically significant reduction in pain, and improvement in function; (Ref: Am J Sports Med. 2023 Jul;51(9):2254-2266); with robust quality & thickness of cartilage tissue demonstrating halt in further disease progression, even at 2 years post-treatment.
          </p>
          <p>
            Our lead indication is Osteoarthritis of the knee. We intend to develop additional products using the pooling technology and enhancements to it for several additional indications including for example Chronic Limb Ischemia, Diabetic Foot Ulcers, and Degenerative Disc Disease.
          </p>
        </div>
  
        <!-- Right: Image -->
        <div class="image">
          <img src="q1.png" alt="Diagram of Knee Affected by Osteoarthritis" />
        </div>
      </div>
    </section>
  </main>
  

  <div class="clinical-summary">
    <h2>Summary of Stempeucel Product Clinical Data</h2>
    <p><strong>Stempeucel<sup>Â®</sup> Product has shown safety & efficacy in Knee OA & Critical Limb Ischemia (BD & PAD) trials.</strong></p>
  
    <div class="section">
      <div class="section-header">
        <div class="square teal"></div>
        <strong>Knee Osteoarthritis (Knee OA) trial, comparing treatment to placebo arms:</strong>
      </div>
      <ul>
        <li><span class="square light"></span> Significant improvement in overall WOMAC composite index (p&lt;0.0001) with <strong>71.43% reduction</strong></li>
        <li><span class="square light"></span> Significant improvement in all WOMAC subscores for pain (p&lt;0.0001) with <strong>73.12% reduction</strong>, physical function (p&lt;0.0001) with <strong>71.46% reduction</strong> and stiffness (p&lt;0.0001) with <strong>77.25% reduction</strong></li>
        <li><span class="square light"></span> Significant improvement in VAS score (p&lt;0.0001) with <strong>64.04% reduction</strong> compared to placebo</li>
        <li><span class="square light"></span> Improvement in pro-inflammatory marker <strong>hsCRP</strong>, anti-inflammatory marker <strong>IL-10 & CTX II</strong> (urine)</li>
        <li><span class="square light"></span> Cartilage quality is maintained in MFT compartment (most commonly involved based on MRI T2 imaging)</li>
        <li><span class="square light"></span> Less number of TKR in Stempeucel arm (1 vs. 4 in placebo) at two years follow up</li>
      </ul>
    </div>
  
    <div class="section">
      <div class="section-header">
        <div class="square teal"></div>
        <strong>In Critical Limb Ischemia (CLI) due to Buerger's Disease and Atherosclerotic PAD:</strong>
      </div>
      <ul>
        <li><span class="square light"></span> Shows significant improvement in primary end points (relief of rest pain & ulcer healing)</li>
        <li><span class="square light"></span> Improved vascularityâ€”seen as development of new collaterals in MRA at six months follow up</li>
      </ul>
    </div>
  </div>
  
        
      
        <!-- Add Image Here -->
        <div class="clinical-image">
          <img src="clinical.png" alt="Stempeucel Clinical Data Summary" />
        </div>
      </section>
      

    <!-- Approval Note -->
    <section class="approval-note">
      <p><strong>StempeucelÂ® is approved by CDSCO (Indian FDA equivalent) for treatment of (1) Grade 2 & 3 Osteoarthritis of the knee in non-obese patients with BMI 30Kg mÂ² (2) No-option CLI due to Bruegers Disease & Artherosclerotic Peripheral Arterial Disease</strong>...</p>
    </section>
  </main>

  <!-- Footer -->
  <footer class="footer">
    <div class="footer-content">
      <div class="footer-section quick-links">
        <h3>Quick Links</h3>
        <div class="quick-links-grid">
          <div><span>â–£</span> Regenerative Medicine</div>
          <div><span>â–£</span> Mechanism of Action</div>
          <div><span>â–£</span> Technology Platform</div>
          <div><span>â–£</span> CMC & Manufacturing</div>
          <div><span>â–£</span> Publications</div>
          <div><span>â–£</span> Press Release</div>
          <div><span>â–£</span> Partners</div>
          <div><span>â–£</span> Investors</div>
          <div><span>â–£</span> Careers</div>
        </div>
      </div>

      <div class="footer-section contact">
        <h3>Contact</h3>
        <p><span>ðŸ“§</span> info@mkcbiotherapeutics.com</p>
        <p><span>ðŸ“§</span> hr@mkcbiotherapeutics.com</p>
      </div>
    </div>

    <div class="footer-bottom">
      <p>Â© 2024 MKC Biotherapeutics, Inc. All rights reserved.</p>
      <div class="footer-links">
        <a href="#">Privacy Policy</a> |
        <a href="#">Terms of Use</a>
      </div>
    </div>
  </footer>

  <!-- JavaScript -->
  <script>
    function toggleMenu() {
      const menu = document.getElementById("mobile-menu");
      menu.classList.toggle("open");
      menu.setAttribute("aria-hidden", !menu.classList.contains("open"));
    }
  </script>
</body>
</html>
